Endpoints in clinical trials: What do our patients consider important? A survey of the Ovarian Cancer National Alliance (OCNA)

Coleman, R.L.; Rd, Alvarez; Herzog, T.J.

doi:10.1016/j.ygyno.2013.04.088

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent online study by Coleman et al (2013) asked ovarian cancer patients to quantify the minimum benefit in PFS that a therapy would have for it to be valuable. The majority of participants selected 5 or more months, and when asked to tradeoff overall survival with toxicity compared to PFS without toxicity, 44% of participants chose the latter while 37% found neither acceptable [ 16 ]. In our study we found that the minimum length of time that participants stated a treatment would be valuable with both mild or moderate to severe side effects was 6 months.…”

Section: Discussionmentioning

confidence: 99%

Experience and Expectations of Ovarian Cancer Patients in Australia

Holliday¹,

Morte²,

Byrne³

et al. 2018

Journal of Oncology

View full text Add to dashboard Cite

Some of the most significant advances in ovarian cancer treatment have been those that result in improvements in progression-free survival (PFS); however there is little research to understand the value that patients place on accessing therapies that result in PFS as a clinical outcome related to survivorship. This study therefore aimed to understand the experience and expectations of women with ovarian cancer in Australia in relation to quality of life (QoL) and treatment options. An online survey collected demographic information and 13 investigator-derived structured interview questions were developed to understand the experience of women with ovarian cancer, their understanding of terminology associated with their condition, and expectations of future treatment. This study demonstrated that ovarian cancer patients equate PFS with being in remission and that patients expect QoL during that time to be good to excellent. Women in this study described excellent QoL as feeling positive and happy and not worrying about cancer, feeling fit and healthy without side effects, and being able to live life as they did before their diagnosis, including the absence of fear of progression or recurrence. It is therefore suggested that there is a positive relationship between PFS and QoL. While it is difficult to quantify QoL and further research is needed, the results of this study suggest that the minimum time that women with ovarian cancer expect in relation to treatments that result in PFS is approximately six months. In the absence of this information, decision-makers are left to make assumptions about the value women place on access to therapeutics that increase PFS, which for this type of cancer is an important aspect of survivorship.

show abstract

Section: Discussionmentioning

confidence: 99%